These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26690657)

  • 1. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.
    Bulotta S; Celano M; Costante G; Russo D
    Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
    Spitzweg C; Bible KC; Hofbauer LC; Morris JC
    Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target therapies for radioiodine refractory advanced thyroid tumors.
    Schlumberger M
    J Endocrinol Invest; 2012; 35(6 Suppl):40-4. PubMed ID: 23014073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
    de la Fouchardière C
    Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S34-9. PubMed ID: 26826481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer.
    Fröhlich E; Wahl R
    Cancer Treat Rev; 2014 Jun; 40(5):665-74. PubMed ID: 24485648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on thyroid cancer treatment.
    Regalbuto C; Frasca F; Pellegriti G; Malandrino P; Marturano I; Di Carlo I; Pezzino V
    Future Oncol; 2012 Oct; 8(10):1331-48. PubMed ID: 23130931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches in the management of radioiodine-refractory thyroid cancer: the molecular targeted therapy era.
    Capdevila J; Argiles G; Rodriguez-Frexinos V; Nuñez I; Tabernero J
    Discov Med; 2010 Feb; 9(45):153-62. PubMed ID: 20193642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy in radioiodine refractory thyroid cancer.
    Pacini F; Brilli L; Marchisotta S
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):520-5. PubMed ID: 19910905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redifferentiating agents in non-radioiodine avid cancer.
    Seregni E; Vellani C; Castellani MR; Maccauro M; Pallotti F; Scaramellini G; Guzzo M; Greco A
    Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):513-9. PubMed ID: 19910904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging molecular therapies of advanced thyroid cancer.
    Catalano MG; Poli R; Pugliese M; Fortunati N; Boccuzzi G
    Mol Aspects Med; 2010 Apr; 31(2):215-26. PubMed ID: 20176050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting autophagy in thyroid cancers.
    Wei W; Hardin H; Luo QY
    Endocr Relat Cancer; 2019 Apr; 26(4):R181-R194. PubMed ID: 30667364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies and thyroid cancer: an update.
    de la Fouchardiere C; Droz JP
    Anticancer Drugs; 2011 Aug; 22(7):688-99. PubMed ID: 21200314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond.
    Bulotta S; Celano M; Costante G; Russo D
    Curr Opin Oncol; 2020 Jan; 32(1):13-19. PubMed ID: 31599772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.
    Marotta V; Colao A; Faggiano A
    Endocrine; 2015 Dec; 50(3):824-5. PubMed ID: 25754914
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer.
    Ibrahim EY; Busaidy NL
    Curr Opin Oncol; 2017 Mar; 29(2):151-158. PubMed ID: 28141684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
    Wadsley J; Ainsworth G; Coulson AB; Garcez K; Moss L; Newbold K; Farnell K; Swain J; Howard H; Beasley M; Weaver A; Wood K; Marshall J; Griffin M; Pascoe A; Du Y; Taprogge J; Flux G; Brown S
    Thyroid; 2023 Sep; 33(9):1119-1123. PubMed ID: 37565288
    [No Abstract]   [Full Text] [Related]  

  • 19. [Lenvatinib in radioiodine refractory thyroid carcinomas].
    de la Fouchardiere C
    Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer.
    Hegazi M; Azadi A; Jain D; Redman R; Perez CA
    Drugs Today (Barc); 2015 Dec; 51(12):689-94. PubMed ID: 26798849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.